Cargando…

PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice

Spinal muscular atrophy (SMA) is a leading genetic cause of infant mortality. The advent of approved treatments for this devastating condition has significantly changed SMA patients' life expectancy and quality of life. Nevertheless, these are not without limitations, and research efforts are u...

Descripción completa

Detalles Bibliográficos
Autores principales: Kordala, Anna J, Stoodley, Jessica, Ahlskog, Nina, Hanifi, Muhammad, Garcia Guerra, Antonio, Bhomra, Amarjit, Lim, Wooi Fang, Murray, Lyndsay M, Talbot, Kevin, Hammond, Suzan M, Wood, Matthew JA, Rinaldi, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630883/
https://www.ncbi.nlm.nih.gov/pubmed/37724723
http://dx.doi.org/10.15252/emmm.202317683
_version_ 1785146054509854720
author Kordala, Anna J
Stoodley, Jessica
Ahlskog, Nina
Hanifi, Muhammad
Garcia Guerra, Antonio
Bhomra, Amarjit
Lim, Wooi Fang
Murray, Lyndsay M
Talbot, Kevin
Hammond, Suzan M
Wood, Matthew JA
Rinaldi, Carlo
author_facet Kordala, Anna J
Stoodley, Jessica
Ahlskog, Nina
Hanifi, Muhammad
Garcia Guerra, Antonio
Bhomra, Amarjit
Lim, Wooi Fang
Murray, Lyndsay M
Talbot, Kevin
Hammond, Suzan M
Wood, Matthew JA
Rinaldi, Carlo
author_sort Kordala, Anna J
collection PubMed
description Spinal muscular atrophy (SMA) is a leading genetic cause of infant mortality. The advent of approved treatments for this devastating condition has significantly changed SMA patients' life expectancy and quality of life. Nevertheless, these are not without limitations, and research efforts are underway to develop new approaches for improved and long‐lasting benefits for patients. Protein arginine methyltransferases (PRMTs) are emerging as druggable epigenetic targets, with several small‐molecule PRMT inhibitors already in clinical trials. From a screen of epigenetic molecules, we have identified MS023, a potent and selective type I PRMT inhibitor able to promote SMN2 exon 7 inclusion in preclinical SMA models. Treatment of SMA mice with MS023 results in amelioration of the disease phenotype, with strong synergistic amplification of the positive effect when delivered in combination with the antisense oligonucleotide nusinersen. Moreover, transcriptomic analysis revealed that MS023 treatment has minimal off‐target effects, and the added benefit is mainly due to targeting neuroinflammation. Our study warrants further clinical investigation of PRMT inhibition both as a stand‐alone and add‐on therapy for SMA.
format Online
Article
Text
id pubmed-10630883
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106308832023-11-15 PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice Kordala, Anna J Stoodley, Jessica Ahlskog, Nina Hanifi, Muhammad Garcia Guerra, Antonio Bhomra, Amarjit Lim, Wooi Fang Murray, Lyndsay M Talbot, Kevin Hammond, Suzan M Wood, Matthew JA Rinaldi, Carlo EMBO Mol Med Articles Spinal muscular atrophy (SMA) is a leading genetic cause of infant mortality. The advent of approved treatments for this devastating condition has significantly changed SMA patients' life expectancy and quality of life. Nevertheless, these are not without limitations, and research efforts are underway to develop new approaches for improved and long‐lasting benefits for patients. Protein arginine methyltransferases (PRMTs) are emerging as druggable epigenetic targets, with several small‐molecule PRMT inhibitors already in clinical trials. From a screen of epigenetic molecules, we have identified MS023, a potent and selective type I PRMT inhibitor able to promote SMN2 exon 7 inclusion in preclinical SMA models. Treatment of SMA mice with MS023 results in amelioration of the disease phenotype, with strong synergistic amplification of the positive effect when delivered in combination with the antisense oligonucleotide nusinersen. Moreover, transcriptomic analysis revealed that MS023 treatment has minimal off‐target effects, and the added benefit is mainly due to targeting neuroinflammation. Our study warrants further clinical investigation of PRMT inhibition both as a stand‐alone and add‐on therapy for SMA. John Wiley and Sons Inc. 2023-09-19 /pmc/articles/PMC10630883/ /pubmed/37724723 http://dx.doi.org/10.15252/emmm.202317683 Text en © 2023 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
Kordala, Anna J
Stoodley, Jessica
Ahlskog, Nina
Hanifi, Muhammad
Garcia Guerra, Antonio
Bhomra, Amarjit
Lim, Wooi Fang
Murray, Lyndsay M
Talbot, Kevin
Hammond, Suzan M
Wood, Matthew JA
Rinaldi, Carlo
PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice
title PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice
title_full PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice
title_fullStr PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice
title_full_unstemmed PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice
title_short PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice
title_sort prmt inhibitor promotes smn2 exon 7 inclusion and synergizes with nusinersen to rescue sma mice
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630883/
https://www.ncbi.nlm.nih.gov/pubmed/37724723
http://dx.doi.org/10.15252/emmm.202317683
work_keys_str_mv AT kordalaannaj prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice
AT stoodleyjessica prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice
AT ahlskognina prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice
AT hanifimuhammad prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice
AT garciaguerraantonio prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice
AT bhomraamarjit prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice
AT limwooifang prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice
AT murraylyndsaym prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice
AT talbotkevin prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice
AT hammondsuzanm prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice
AT woodmatthewja prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice
AT rinaldicarlo prmtinhibitorpromotessmn2exon7inclusionandsynergizeswithnusinersentorescuesmamice